Dec. 8 Event: Unpacking the Prescription Drug Provisions of the Build Back Better Act
As the Build Back Better Act shifts from the House to the Senate, there’s considerable interest in provisions that would lower the cost of prescription drugs.
View the Latest: Build Back Better
Filter
-
-
Medicaid Enrollment Churn and Implications for Continuous Coverage Policies
Issue BriefRecent policy actions and proposals in Medicaid have renewed focus on the problem of churn, or temporary loss of coverage in which enrollees disenroll and then re-enroll within a short period of time. We find that 10% of full-benefit enrollees have a gap in coverage of less than a year, and rates are higher for children and adults compared to aged and people with disabilities. Churn has implications for access to care as well as administrative costs faced by states.
-
Medicaid Outpatient Prescription Drug Trends During the COVID-19 Pandemic
Issue BriefThis data note describes Medicaid prescription drug utilization and spending trends in calendar year 2020 compared to previous years to explore how the pandemic impacted Medicaid prescription drug utilization and spending.
-
Employers Strengthen Paid Leave Benefits During the COVID-19 Pandemic: Findings from the 2021 KFF Employer Health Benefits Survey
Issue BriefSome employers announced changes to their paid leave policies in light of the COVID-19 pandemic to ensure more workers have access to paid leave and to reduce the risk of workers coming to work sick. This data note presents findings from the 2021 KFF Employer Health Benefits Survey on the share of workers who are employed by firms that began offering paid leave benefits or expanded their existing benefits since the COVID-19 pandemic began.
-
Potential Costs and Impact of Health Provisions in the Build Back Better Act
Issue BriefA summary of 10 of the major health coverage and financing provisions of the current Build Back Better Act, with discussion of the potential implications for people and the federal budget.
-
Millions of Medicare Beneficiaries Use Prescription Drugs That Could Be Subject to Price Negotiation, But Build Back Better Act Provision Exempts Many Drugs With High Federal Spending
News ReleaseTwenty drugs and dozens of insulin products used by 8.5 million Medicare beneficiaries would be subject to government drug price negotiation if the Build Back Better Act (BBBA) were enacted and fully implemented in 2022, according to a new KFF analysis.
-
Out-of-pocket spending on insulin among people with private insurance
Issue BriefThis analysis of insurance claims data finds that Congressional proposals to set a $35 per month cap on what people pay out of pocket for insulin would provide financial relief to at least 1 out of 5 insulin users with different types of private health insurance.
-
Build Back Better Would Change the Ways Low-Income People get Health Insurance
Issue BriefThe Build Back Better Act would make a number of changes to the way people get health insurance and how health care is financed, including by temporarily closing the Medicaid coverage gap.
-
Maternal Health in the Build Back Better Act
Policy WatchThis policy watch highlights the different provisions and potential impact on parents and children in America. From expanding Medicaid postpartum coverage to establishing a national paid family leave policy, the BBBA could provide more support to states and community organizations working to improve maternal health.
-
New KFF Resource Explains Key Provisions for Maternal Health Within the Build Back Better Act
News ReleaseIf passed, the Build Back Better Act (BBBA) would include several provisions to improve maternal health, particularly for people of color. A new KFF Policy Watch explains the different provisions, their potential impact on parents and children, as well as the projected federal costs of these proposals.